Australia's most trusted
source of pharma news
Friday, 26 June 2026
Posted 26 June 2026 PM
The pharma industry’s mood is improving. The Biopharma Sentiment Index (BPSI) headline score climbed to 96 in Q2 2026, up from 90 in Q1 and just 78 in Q4 2025. The result put sentiment close to the neutral figure of 100.
While positivity was generally on the rise across the board, the biggest negative was respondents’ views on the future of the funding climate.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.